[ad_1]
Live webcast presentation, Wednesday, April 3 at 1:35 pm ET
Ocala, Florida, March 28, 2024 (GLOBE NEWSWIRE) — AIM Immunotechnologies, Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that Thomas K. Equels, MS JD, Chief Executive Officer of AIM ImmunoTech, will attend the MedInvest Biotech and Pharmaceutical Investor Conference in New York, NY on Wednesday, April 3, 2024, United States 1:35pm ET.
In addition to the presentation, management will participate in one-on-one meetings with members of the accredited investor community who have registered for the conference. For more information about the event, visit the conference website.
A webcast of this presentation will be available on the Events page of the Investors section of the Company’s website (www.aimimmuno.com).
About AIM Immunotechnologies, Inc.
AIM ImmunoTech Inc. is an immunopharmaceutical company focused on researching and developing therapies to treat multiple types of cancer, immune diseases and viral diseases, including COVID-19.The company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod) is a dsRNA and highly selective TLR3 agonist immunomodulator with broad-spectrum activity in clinical trials targeting globally important cancers, viral diseases, and immune system diseases.
For more information, visit aimimmuno.com and connect with the company on X, LinkedIn and Facebook.
CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com
[ad_2]
Source link